The global prostate cancer diagnostics market is projected to reach USD 17.01 billion by 2034, growing from USD 9.72 billion in 2025 at a CAGR of 6.42% from 2025 to 2034. This growth is driven by the rising incidences of prostate cancer, advancements in diagnostic tools, and increased government initiatives supporting early detection and screening.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Prostate Cancer Diagnostics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Prostate Cancer Diagnostics Market, by Test Type
8.1.1 Preliminary Tests
8.1.1.1. Market Revenue and Forecast
8.1.2. PSA Tests
8.1.2.1. Market Revenue and Forecast
8.1.3. Free PSA Test
8.1.3.1. Market Revenue and Forecast
8.1.4. Total PSA Test
8.1.4.1. Market Revenue and Forecast
8.1.5. Other Preliminary Tests
8.1.5.1. Market Revenue and Forecast
8.1.6. Confirmatory Tests
8.1.6.1. Market Revenue and Forecast
8.1.7. Pca3 Test
8.1.7.1. Market Revenue and Forecast
8.1.8. Trans-Rectal Ultrasound
8.1.8.1. Market Revenue and Forecast
8.1.9. Biopsy Test
8.1.9.1. Market Revenue and Forecast
9.1. Prostate Cancer Diagnostics Market, by Type
9.1.1. Adenocarcinoma
9.1.1.1. Market Revenue and Forecast
9.1.2. Interstitial Cell Carcinoma
9.1.2.1. Market Revenue and Forecast
9.1.3. Other
9.1.3.1. Market Revenue and Forecast
10.1. Prostate Cancer Diagnostics Market, by End-Use
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast
10.1.2. Home Care
10.1.2.1. Market Revenue and Forecast
10.1.3. Outpatient Facilities
10.1.3.1. Market Revenue and Forecast
10.1.4. Research & Manufacturing
10.1.4.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Test Type
11.1.2. Market Revenue and Forecast, by Type
11.1.3. Market Revenue and Forecast, by End-Use
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Test Type
11.1.4.2. Market Revenue and Forecast, by Type
11.1.4.3. Market Revenue and Forecast, by End-Use
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Test Type
11.1.5.2. Market Revenue and Forecast, by Type
11.1.5.3. Market Revenue and Forecast, by End-Use
11.2. Europe
11.2.1. Market Revenue and Forecast, by Test Type
11.2.2. Market Revenue and Forecast, by Type
11.2.3. Market Revenue and Forecast, by End-Use
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Test Type
11.2.4.2. Market Revenue and Forecast, by Type
11.2.4.3. Market Revenue and Forecast, by End-Use
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Test Type
11.2.5.2. Market Revenue and Forecast, by Type
11.2.5.3. Market Revenue and Forecast, by End-Use
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Test Type
11.2.6.2. Market Revenue and Forecast, by Type
11.2.6.3. Market Revenue and Forecast, by End-Use
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Test Type
11.2.7.2. Market Revenue and Forecast, by Type
11.2.7.3. Market Revenue and Forecast, by End-Use
11.3. APAC
11.3.1. Market Revenue and Forecast, by Test Type
11.3.2. Market Revenue and Forecast, by Type
11.3.3. Market Revenue and Forecast, by End-Use
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Test Type
11.3.4.2. Market Revenue and Forecast, by Type
11.3.4.3. Market Revenue and Forecast, by End-Use
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Test Type
11.3.5.2. Market Revenue and Forecast, by Type
11.3.5.3. Market Revenue and Forecast, by End-Use
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Test Type
11.3.6.2. Market Revenue and Forecast, by Type
11.3.6.3. Market Revenue and Forecast, by End-Use
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Test Type
11.3.7.2. Market Revenue and Forecast, by Type
11.3.7.3. Market Revenue and Forecast, by End-Use
11.4. MEA
11.4.1. Market Revenue and Forecast, by Test Type
11.4.2. Market Revenue and Forecast, by Type
11.4.3. Market Revenue and Forecast, by End-Use
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Test Type
11.4.4.2. Market Revenue and Forecast, by Type
11.4.4.3. Market Revenue and Forecast, by End-Use
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Test Type
11.4.5.2. Market Revenue and Forecast, by Type
11.4.5.3. Market Revenue and Forecast, by End-Use
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Test Type
11.4.6.2. Market Revenue and Forecast, by Type
11.4.6.3. Market Revenue and Forecast, by End-Use
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Test Type
11.4.7.2. Market Revenue and Forecast, by Type
11.4.7.3. Market Revenue and Forecast, by End-Use
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Test Type
11.5.2. Market Revenue and Forecast, by Type
11.5.3. Market Revenue and Forecast, by End-Use
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Test Type
11.5.4.2. Market Revenue and Forecast, by Type
11.5.4.3. Market Revenue and Forecast, by End-Use
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Test Type
11.5.5.2. Market Revenue and Forecast, by Type
11.5.5.3. Market Revenue and Forecast, by End-Use
12.1. MDx Health
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Myriad Genetics, Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Abbott Laboratories
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. F. Hoffman-La Roche AG
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Bayer AG
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Siemens Healthcare GmbH
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. OPKO Health, Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Genomic Health.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Pfizer Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Humasis
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description